Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

INDV vs RBBN vs AVPT vs QLYS vs EGHT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
INDV
Indivior Pharmaceuticals Inc

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$4.94B
5Y Perf.+890.0%
RBBN
Ribbon Communications Inc.

Telecommunications Services

Communication ServicesNASDAQ • US
Market Cap$472M
5Y Perf.-38.9%
AVPT
AvePoint, Inc.

Software - Infrastructure

TechnologyNASDAQ • US
Market Cap$2.23B
5Y Perf.+5.4%
QLYS
Qualys, Inc.

Software - Infrastructure

TechnologyNASDAQ • US
Market Cap$3.34B
5Y Perf.-17.7%
EGHT
8x8, Inc.

Software - Application

TechnologyNASDAQ • US
Market Cap$372M
5Y Perf.-81.6%

INDV vs RBBN vs AVPT vs QLYS vs EGHT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
INDV logoINDV
RBBN logoRBBN
AVPT logoAVPT
QLYS logoQLYS
EGHT logoEGHT
IndustryDrug Manufacturers - Specialty & GenericTelecommunications ServicesSoftware - InfrastructureSoftware - InfrastructureSoftware - Application
Market Cap$4.94B$472M$2.23B$3.34B$372M
Revenue (TTM)$1.29B$826M$444M$685M$728M
Net Income (TTM)$251M$31M$47M$201M$-4M
Gross Margin83.1%48.7%73.7%83.1%65.7%
Operating Margin33.3%-0.7%9.6%33.7%2.6%
Forward P/E12.7x20.7x27.7x12.9x7.3x
Total Debt$351M$405M$10M$97M$410M
Cash & Equiv.$195M$96M$481M$250M$88M

INDV vs RBBN vs AVPT vs QLYS vs EGHTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

INDV
RBBN
AVPT
QLYS
EGHT
StockMay 20May 26Return
Indivior Pharmaceut… (INDV)100990.0+890.0%
Ribbon Communicatio… (RBBN)10061.1-38.9%
AvePoint, Inc. (AVPT)100105.4+5.4%
Qualys, Inc. (QLYS)10082.3-17.7%
8x8, Inc. (EGHT)10018.4-81.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: INDV vs RBBN vs AVPT vs QLYS vs EGHT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: QLYS leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Indivior Pharmaceuticals Inc is the stronger pick specifically for recent price momentum and sentiment. AVPT and EGHT also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
INDV
Indivior Pharmaceuticals Inc
The Long-Run Compounder

INDV is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 281.7% 10Y total return vs QLYS's 267.2%
  • +244.9% vs AVPT's -40.0%
Best for: long-term compounding
RBBN
Ribbon Communications Inc.
The Communication Services Pick

Among these 5 stocks, RBBN doesn't own a clear edge in any measured category.

Best for: communication services exposure
AVPT
AvePoint, Inc.
The Growth Play

AVPT ranks third and is worth considering specifically for growth exposure.

  • Rev growth 26.9%, EPS growth 193.8%, 3Y rev CAGR 21.8%
  • 26.9% revenue growth vs EGHT's -1.9%
Best for: growth exposure
QLYS
Qualys, Inc.
The Income Pick

QLYS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • beta 0.53
  • Lower volatility, beta 0.53, Low D/E 17.3%, current ratio 1.41x
  • Beta 0.53, current ratio 1.41x
  • 29.4% margin vs EGHT's -0.5%
Best for: income & stability and sleep-well-at-night
EGHT
8x8, Inc.
The Value Play

EGHT is the clearest fit if your priority is value.

  • Lower P/E (7.3x vs 12.9x)
Best for: value
See the full category breakdown
CategoryWinnerWhy
GrowthAVPT logoAVPT26.9% revenue growth vs EGHT's -1.9%
ValueEGHT logoEGHTLower P/E (7.3x vs 12.9x)
Quality / MarginsQLYS logoQLYS29.4% margin vs EGHT's -0.5%
Stability / SafetyQLYS logoQLYSBeta 0.53 vs RBBN's 1.49, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)INDV logoINDV+244.9% vs AVPT's -40.0%
Efficiency (ROA)QLYS logoQLYS19.1% ROA vs EGHT's -0.6%, ROIC 47.5% vs 2.5%

INDV vs RBBN vs AVPT vs QLYS vs EGHT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

INDVIndivior Pharmaceuticals Inc
FY 2025
Reportable Segment
100.0%$1.2B
RBBNRibbon Communications Inc.
FY 2025
Cloud and Edge
60.6%$511M
IP Optical Networks
39.4%$333M
AVPTAvePoint, Inc.
FY 2024
SaaS
76.1%$319M
Termed License and Support
10.7%$45M
Service
10.5%$44M
Maintenance
2.7%$11M
QLYSQualys, Inc.
FY 2025
Reportable Segment
100.0%$669M
EGHT8x8, Inc.
FY 2025
Service
96.9%$693M
Product and Service, Other
3.1%$22M

INDV vs RBBN vs AVPT vs QLYS vs EGHT — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLINDVLAGGINGRBBN

Income & Cash Flow (Last 12 Months)

QLYS leads this category, winning 3 of 6 comparable metrics.

INDV is the larger business by revenue, generating $1.3B annually — 2.9x AVPT's $444M. QLYS is the more profitable business, keeping 29.4% of every revenue dollar as net income compared to EGHT's -0.5%. On growth, AVPT holds the edge at +26.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricINDV logoINDVIndivior Pharmace…RBBN logoRBBNRibbon Communicat…AVPT logoAVPTAvePoint, Inc.QLYS logoQLYSQualys, Inc.EGHT logoEGHT8x8, Inc.
RevenueTrailing 12 months$1.3B$826M$444M$685M$728M
EBITDAEarnings before interest/tax$447M$40M$47M$241M$48M
Net IncomeAfter-tax profit$251M$31M$47M$201M-$4M
Free Cash FlowCash after capex-$185M$17M$105M$290M$62M
Gross MarginGross profit ÷ Revenue+83.1%+48.7%+73.7%+83.1%+65.7%
Operating MarginEBIT ÷ Revenue+33.3%-0.7%+9.6%+33.7%+2.6%
Net MarginNet income ÷ Revenue+19.4%+3.8%+10.5%+29.4%-0.5%
FCF MarginFCF ÷ Revenue-14.3%+2.0%+23.6%+42.4%+8.6%
Rev. Growth (YoY)Latest quarter vs prior year+19.2%-10.3%+26.0%+9.8%+5.0%
EPS Growth (YoY)Latest quarter vs prior year+81.6%-33.3%+3.6%+10.1%+59.6%
QLYS leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

EGHT leads this category, winning 4 of 6 comparable metrics.

At 12.2x trailing earnings, RBBN trades at a 82% valuation discount to AVPT's 68.8x P/E. On an enterprise value basis, RBBN's 9.6x EV/EBITDA is more attractive than AVPT's 44.8x.

MetricINDV logoINDVIndivior Pharmace…RBBN logoRBBNRibbon Communicat…AVPT logoAVPTAvePoint, Inc.QLYS logoQLYSQualys, Inc.EGHT logoEGHT8x8, Inc.
Market CapShares × price$4.9B$472M$2.2B$3.3B$372M
Enterprise ValueMkt cap + debt − cash$5.1B$781M$1.8B$3.2B$694M
Trailing P/EPrice ÷ TTM EPS24.15x12.23x68.80x17.45x-12.71x
Forward P/EPrice ÷ next-FY EPS est.12.65x20.69x27.75x12.87x7.27x
PEG RatioP/E ÷ EPS growth rate0.90x
EV / EBITDAEnterprise value multiple17.88x9.57x44.79x13.49x12.76x
Price / SalesMarket cap ÷ Revenue3.99x0.56x5.31x5.00x0.52x
Price / BookPrice ÷ Book value/share1.08x4.94x6.17x2.84x
Price / FCFMarket cap ÷ FCF18.13x27.32x10.98x7.43x
EGHT leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

AVPT leads this category, winning 5 of 9 comparable metrics.

QLYS delivers a 37.2% return on equity — every $100 of shareholder capital generates $37 in annual profit, vs $-3 for EGHT. AVPT carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to EGHT's 3.36x. On the Piotroski fundamental quality scale (0–9), AVPT scores 6/9 vs INDV's 4/9, reflecting solid financial health.

MetricINDV logoINDVIndivior Pharmace…RBBN logoRBBNRibbon Communicat…AVPT logoAVPTAvePoint, Inc.QLYS logoQLYSQualys, Inc.EGHT logoEGHT8x8, Inc.
ROE (TTM)Return on equity+7.9%+10.2%+37.2%-2.7%
ROA (TTM)Return on assets+19.1%+2.7%+6.3%+19.1%-0.6%
ROICReturn on invested capital+3.4%+2.1%+11.4%+47.5%+2.5%
ROCEReturn on capital employed+79.1%+2.4%+8.1%+37.8%+2.8%
Piotroski ScoreFundamental quality 0–945665
Debt / EquityFinancial leverage0.90x0.02x0.17x3.36x
Net DebtTotal debt minus cash$156M$309M-$471M-$153M$322M
Cash & Equiv.Liquid assets$195M$96M$481M$250M$88M
Total DebtShort + long-term debt$351M$405M$10M$97M$410M
Interest CoverageEBIT ÷ Interest expense10.88x-0.02x0.69x
AVPT leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

INDV leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in INDV five years ago would be worth $36,837 today (with dividends reinvested), compared to $922 for EGHT. Over the past 12 months, INDV leads with a +244.9% total return vs AVPT's -40.0%. The 3-year compound annual growth rate (CAGR) favors AVPT at 32.6% vs QLYS's -6.3% — a key indicator of consistent wealth creation.

MetricINDV logoINDVIndivior Pharmace…RBBN logoRBBNRibbon Communicat…AVPT logoAVPTAvePoint, Inc.QLYS logoQLYSQualys, Inc.EGHT logoEGHT8x8, Inc.
YTD ReturnYear-to-date+10.8%-7.2%-21.9%-27.5%+41.3%
1-Year ReturnPast 12 months+244.9%-11.8%-40.0%-25.6%+51.7%
3-Year ReturnCumulative with dividends+97.0%+1.9%+133.0%-17.7%-8.2%
5-Year ReturnCumulative with dividends+268.4%-61.0%+1.7%-3.1%-90.8%
10-Year ReturnCumulative with dividends+281.7%-68.2%+5.5%+267.2%-77.0%
CAGR (3Y)Annualised 3-year return+25.4%+0.6%+32.6%-6.3%-2.8%
INDV leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — INDV and QLYS each lead in 1 of 2 comparable metrics.

QLYS is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than RBBN's 1.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INDV currently trades 96.6% from its 52-week high vs AVPT's 51.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricINDV logoINDVIndivior Pharmace…RBBN logoRBBNRibbon Communicat…AVPT logoAVPTAvePoint, Inc.QLYS logoQLYSQualys, Inc.EGHT logoEGHT8x8, Inc.
Beta (5Y)Sensitivity to S&P 5000.68x1.49x1.06x0.53x1.49x
52-Week HighHighest price in past year$41.00$4.29$20.25$155.47$2.88
52-Week LowLowest price in past year$10.63$1.80$8.83$74.51$1.56
% of 52W HighCurrent price vs 52-week peak+96.6%+62.7%+51.0%+61.1%+92.7%
RSI (14)Momentum oscillator 0–10079.654.354.154.261.1
Avg Volume (50D)Average daily shares traded2.6M879K1.6M773K1.2M
Evenly matched — INDV and QLYS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: INDV as "Buy", RBBN as "Buy", AVPT as "Buy", QLYS as "Hold", EGHT as "Hold". Consensus price targets imply 640.4% upside for EGHT (target: $20) vs 12.8% for INDV (target: $45).

MetricINDV logoINDVIndivior Pharmace…RBBN logoRBBNRibbon Communicat…AVPT logoAVPTAvePoint, Inc.QLYS logoQLYSQualys, Inc.EGHT logoEGHT8x8, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHoldHold
Price TargetConsensus 12-month target$44.67$3.50$17.50$134.30$19.77
# AnalystsCovering analysts38124828
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+0.2%+1.9%+2.2%+5.5%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

QLYS leads in 1 of 6 categories (Income & Cash Flow). EGHT leads in 1 (Valuation Metrics). 1 tied.

Best OverallIndivior Pharmaceuticals Inc (INDV)Leads 1 of 6 categories
Loading custom metrics...

INDV vs RBBN vs AVPT vs QLYS vs EGHT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is INDV or RBBN or AVPT or QLYS or EGHT a better buy right now?

For growth investors, AvePoint, Inc.

(AVPT) is the stronger pick with 26. 9% revenue growth year-over-year, versus -1. 9% for 8x8, Inc. (EGHT). Ribbon Communications Inc. (RBBN) offers the better valuation at 12. 2x trailing P/E (20. 7x forward), making it the more compelling value choice. Analysts rate Indivior Pharmaceuticals Inc (INDV) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — INDV or RBBN or AVPT or QLYS or EGHT?

On trailing P/E, Ribbon Communications Inc.

(RBBN) is the cheapest at 12. 2x versus AvePoint, Inc. at 68. 8x. On forward P/E, 8x8, Inc. is actually cheaper at 7. 3x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — INDV or RBBN or AVPT or QLYS or EGHT?

Over the past 5 years, Indivior Pharmaceuticals Inc (INDV) delivered a total return of +268.

4%, compared to -90. 8% for 8x8, Inc. (EGHT). Over 10 years, the gap is even starker: INDV returned +281. 7% versus EGHT's -77. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — INDV or RBBN or AVPT or QLYS or EGHT?

By beta (market sensitivity over 5 years), Qualys, Inc.

(QLYS) is the lower-risk stock at 0. 53β versus Ribbon Communications Inc. 's 1. 49β — meaning RBBN is approximately 181% more volatile than QLYS relative to the S&P 500. On balance sheet safety, AvePoint, Inc. (AVPT) carries a lower debt/equity ratio of 2% versus 3% for 8x8, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — INDV or RBBN or AVPT or QLYS or EGHT?

By revenue growth (latest reported year), AvePoint, Inc.

(AVPT) is pulling ahead at 26. 9% versus -1. 9% for 8x8, Inc. (EGHT). On earnings-per-share growth, the picture is similar: Indivior Pharmaceuticals Inc grew EPS 108. 3% year-over-year, compared to 17. 0% for Qualys, Inc.. Over a 3-year CAGR, AVPT leads at 21. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — INDV or RBBN or AVPT or QLYS or EGHT?

Qualys, Inc.

(QLYS) is the more profitable company, earning 29. 6% net margin versus -3. 8% for 8x8, Inc. — meaning it keeps 29. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QLYS leads at 33. 2% versus 2. 1% for EGHT. At the gross margin level — before operating expenses — QLYS leads at 82. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is INDV or RBBN or AVPT or QLYS or EGHT more undervalued right now?

On forward earnings alone, 8x8, Inc.

(EGHT) trades at 7. 3x forward P/E versus 27. 7x for AvePoint, Inc. — 20. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EGHT: 640. 4% to $19. 77.

08

Which pays a better dividend — INDV or RBBN or AVPT or QLYS or EGHT?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is INDV or RBBN or AVPT or QLYS or EGHT better for a retirement portfolio?

For long-horizon retirement investors, Qualys, Inc.

(QLYS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 53), +267. 2% 10Y return). Both have compounded well over 10 years (QLYS: +267. 2%, EGHT: -77. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between INDV and RBBN and AVPT and QLYS and EGHT?

These companies operate in different sectors (INDV (Healthcare) and RBBN (Communication Services) and AVPT (Technology) and QLYS (Technology) and EGHT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: INDV is a small-cap quality compounder stock; RBBN is a small-cap deep-value stock; AVPT is a small-cap high-growth stock; QLYS is a small-cap deep-value stock; EGHT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

INDV

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 9%
  • Net Margin > 11%
Run This Screen
Stocks Like

RBBN

Quality Business

  • Sector: Communication Services
  • Market Cap > $100B
  • Gross Margin > 29%
Run This Screen
Stocks Like

AVPT

High-Growth Compounder

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 12%
  • Net Margin > 6%
Run This Screen
Stocks Like

QLYS

Quality Mega-Cap Compounder

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 17%
Run This Screen
Stocks Like

EGHT

Quality Business

  • Sector: Technology
  • Market Cap > $100B
  • Gross Margin > 39%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform INDV and RBBN and AVPT and QLYS and EGHT on the metrics below

Revenue Growth>
%
(INDV: 19.2% · RBBN: -10.3%)
Net Margin>
%
(INDV: 19.4% · RBBN: 3.8%)
P/E Ratio<
x
(INDV: 24.1x · RBBN: 12.2x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.